GILEAD SCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 65.96 USD | +2.14% |
|
+1.82% | -18.58% |
| 09/05 | Declaration of Voting Results by Gilead Sciences | CI |
| 09/05 | Declaration of Voting Results by Gilead Sciences | CI |
ETFs positioned on Gilead Sciences, Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 13.99% | 0 M€ | +12.39% | - | |
| 8.10% | 0 M€ | 0.00% | - | |
| 8.06% | 0 M€ | 0.00% | - | |
| 5.23% | 2 M€ | -.--% | ||
| 3.80% | 7 M€ | -.--% | - | |
| 3.55% | 0 M€ | -2.17% | - | |
| 2.90% | 0 M€ | +0.72% | ||
| 2.66% | 0 M€ | +7.69% | - | |
| 2.62% | 0 M€ | +4.18% | ||
| 2.58% | 0 M€ | +7.34% | - | |
| 2.27% | 0 M€ | +9.27% | ||
| 1.67% | 1 M€ | +2.21% | - | |
| 1.48% | 9 M€ | -4.31% | - | |
| 1.26% | 0 M€ | +4.88% | ||
| 1.26% | 0 M€ | +6.29% | ||
| 1.23% | 4,592 M€ | +11.18% | ||
| 1.21% | 0 M€ | +8.06% | ||
| 1.16% | 0 M€ | +8.99% | ||
| 1.04% | 0 M€ | +5.32% | ||
| 1.01% | 0 M€ | +2.39% | ||
| 1.00% | 5 M€ | -72.95% | - | |
| 0.98% | 0 M€ | 0.00% | - | |
| 0.96% | 2 M€ | +20.44% | ||
| 0.95% | 9 M€ | -.--% | - |
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
Pharmaceuticals
Calendar
14/05/2024
- BofA Securities Health Care Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
65.96
USD
Average target price
82.93
USD
Spread / Average Target
+25.73%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -18.58% | 82.18B | |
| +30.38% | 684B | |
| +26.51% | 568B | |
| -4.36% | 361B | |
| +19.30% | 329B | |
| +3.73% | 284B | |
| +16.70% | 240B | |
| +8.78% | 208B | |
| -7.93% | 200B | |
| +7.68% | 166B |
- Stock Market
- Equities
- GILD Stock
- Funds and ETFs Gilead Sciences, Inc.